A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Camptothecin
  • Neoplasms

abstract

  • The recommended phase II dose with irinotecan 100 mg/m(2) is flavopiridol 60 mg/m(2) and with irinotecan 125 mg/m(2) is flavopiridol 50 mg/m(2). Toxicity can be predicted by baseline bilirubin. Clinical activity is encouraging and may correlate to changes in p21 and Drg1 levels in patients with wild type p53 tumors following therapy.

publication date

  • May 15, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-04-2651

PubMed ID

  • 15897584

Additional Document Info

start page

  • 3836

end page

  • 45

volume

  • 11

number

  • 10